171 related articles for article (PubMed ID: 31704599)
1. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy.
Schraag A; Klumpp B; Afat S; Gatidis S; Nikolaou K; Eigentler TK; Othman AE
Eur J Radiol; 2019 Dec; 121():108688. PubMed ID: 31704599
[TBL] [Abstract][Full Text] [Related]
2. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.
Durot C; Mulé S; Soyer P; Marchal A; Grange F; Hoeffel C
Eur Radiol; 2019 Jun; 29(6):3183-3191. PubMed ID: 30645669
[TBL] [Abstract][Full Text] [Related]
3. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Mulé S; Thiefin G; Costentin C; Durot C; Rahmouni A; Luciani A; Hoeffel C
Radiology; 2018 Aug; 288(2):445-455. PubMed ID: 29584597
[TBL] [Abstract][Full Text] [Related]
4. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
[TBL] [Abstract][Full Text] [Related]
5. CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma.
Bonnin A; Durot C; Barat M; Djelouah M; Grange F; Mulé S; Soyer P; Hoeffel C
Diagn Interv Imaging; 2022 Feb; 103(2):97-102. PubMed ID: 34666945
[TBL] [Abstract][Full Text] [Related]
6. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
[TBL] [Abstract][Full Text] [Related]
7. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
[TBL] [Abstract][Full Text] [Related]
8. Metastatic melanoma treated by immunotherapy: discovering prognostic markers from radiomics analysis of pretreatment CT with feature selection and classification.
Ungan G; Lavandier AF; Rouanet J; Hordonneau C; Chauveau B; Pereira B; Boyer L; Garcier JM; Mansard S; Bartoli A; Magnin B
Int J Comput Assist Radiol Surg; 2022 Oct; 17(10):1867-1877. PubMed ID: 35650345
[TBL] [Abstract][Full Text] [Related]
9. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
Nishino M; Giobbie-Hurder A; Manos MP; Bailey N; Buchbinder EI; Ott PA; Ramaiya NH; Hodi FS
Clin Cancer Res; 2017 Aug; 23(16):4671-4679. PubMed ID: 28592629
[No Abstract] [Full Text] [Related]
11. Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy.
Almansour H; Afat S; Serna-Higuita LM; Amaral T; Schraag A; Peisen F; Brendlin A; Seith F; Klumpp B; Eigentler TK; Othman AE
Acad Radiol; 2022 Apr; 29(4):514-522. PubMed ID: 34130924
[TBL] [Abstract][Full Text] [Related]
12. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
13. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
[TBL] [Abstract][Full Text] [Related]
14. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.
Janka EA; Ványai B; Szabó IL; Toka-Farkas T; Várvölgyi T; Kapitány A; Szegedi A; Emri G
Front Oncol; 2023; 13():1237643. PubMed ID: 37664072
[TBL] [Abstract][Full Text] [Related]
15. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.
Weide B; Richter S; Büttner P; Leiter U; Forschner A; Bauer J; Held L; Eigentler TK; Meier F; Garbe C
PLoS One; 2013; 8(11):e81624. PubMed ID: 24312329
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
17. A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma.
Brendlin AS; Peisen F; Almansour H; Afat S; Eigentler T; Amaral T; Faby S; Calvarons AF; Nikolaou K; Othman AE
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795006
[TBL] [Abstract][Full Text] [Related]
18. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
20. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
